Collectively, these findings underscore the potent anti-inflammatory potential of MV-DDSs, which act through the precise modulation of key signaling pathways such as NF-κB and NLRP3, offering a promising therapeutic strategy for the treatment of IBD. Here, NFKB1 is linked to inflammatory bowel disease.